New drug combo targets tough breast cancer in early trial

NCT ID NCT04572295

Completed Disease control Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a common type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 participants will take part to guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apert syndrome breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Locations

Eisai Trial Site 1

Koto-ku, Tokyo, Japan
Eisai Trial Site 10

Kitaadachi-gun, Saitama, Japan
Eisai Trial Site 11

Nagoya, Aichi-ken, Japan
Eisai Trial Site 2

Shinagawa-ku, Tokyo, Japan
Eisai Trial Site 3

Chuo-ku, Tokyo, Japan
Eisai Trial Site 4

Sendai, Miyagi, Japan
Eisai Trial Site 5

Yokohama, Kanagawa, Japan
Eisai Trial Site 6

Kashiwa, Chiba, Japan
Eisai Trial Site 7

Chuo-ku, Osaka, Japan
Eisai Trial Site 8

Shinjuku-ku, Tokyo, Japan
Eisai Trial Site 9

Matsuyama, Ehime, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.